Volitionrx limited announces exercise of over-allotment option by underwriters

Henderson, nev. , june 23, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to volition from the offering to approximately $19.0 million, before deducting underwriting commissions and other offering expenses payable by volition.
VNRX Ratings Summary
VNRX Quant Ranking